Login to Your Account


Mutational signature approach could broaden PARP inhibitors’ reach

By Anette Breindl
Senior Science Editor

Tuesday, March 14, 2017

Comprehensive analysis of mutational patterns has demonstrated that roughly 20 percent of breast tumors showed a mutational signature that was characteristic of BRCA mutations. Even without BRCA mutations, the mutational pattern suggests such tumors might have the same sensitivity to poly ADP-ribose polymerase (PARP) inhibitors as tumors with detectable BRCA mutations.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription